Orexigen Estimates RAISED and 4 Stock Analyses Not to Miss

J. C. Penney Company, Inc. (NYSE:JCP) may be able to gain an EPS of $5.50 per share by the end of five years, according to Argus’ beliefs, but the firm decreased its price target to $35 from $49 on the stock. The firm keeps a Buy rating on the shares.

Linkedin Corporation (NYSE:LNKD): According to Susquehanna, its membership tracker suggests a constant solid execution during LinkedIn’s Q2. The firm gives shares a Positive rating and a $140 price target.

Don’t Miss: Is There MORE TROUBLE for the PC Market on the Way?

Teradyne Inc. (NYSE:TER): Susquehanna’s checks suggest that Q2 deal activity and 2H 2012 pipelines are still robust. Due to weakness, the firm recommends buying shares, and it keeps its Positive rating and $91 price target on the stock.

Orexigen Therapeutics, Inc. (NASDAQ:OREX) estimates were increased by Bank of America Merrill Lynch due to the enrollment for its Light Study trial’s exceeding of expectations. Shares have a Buy rating.

MGM Resorts International (NYSE:MGM): Growth forecasts for the Macau gaming sector have been reduced by Stifel Nicolaus over the next 18 months, while the firm also reduces its outlook for Macau gross gaming revenue from 14%-17% to 12%-15%. The firm thinks most of the risk has already been factored into stocks, but it still reduced its target from  MGM (NYSE:MGM) to $18 from $20, and on Las Vegas Sands (NYSE:LVS) to $53 from $69. The firm mentioned MGM as its top pick in the sector and keeps a Buy rating on the two stocks. The firm decreased Wynn Resorts (NASDAQ:WYNN) estimated, and keeps a Hold rating on those shares.

Don’t Miss: Why is NBC Demanding This SPLIT?

Want news like this in real-time so you can get an edge? Click here for Wall St. Cheat Sheet Pro.